Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer

Jacob M. Sands, Stéphane Champiat, Horst-Dieter Hummel, Kelly G. Paulson, Hossein Borghaei, Jean Bustamante Alvarez, David P. Carbone, Jennifer W. Carlisle, Noura J. Choudhury, Jeffrey M. Clarke, Shirish M. Gadgeel, Hiroki Izumi, Alejandro Navarro, Sally C. M. Lau, Philip E. Lammers, Shuang Huang, Ali Hamidi, Sujoy Mukherjee, Taofeek K. Owonikoko
doi: https://doi.org/10.1101/2024.10.11.24315056

Article usage

Article usage: October 2024 to January 2025

AbstractFullPdf
Oct 202461125183
Nov 202447146183
Dec 202426951150
Jan 2025811125
Back to top
Posted November 23, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer
Jacob M. Sands, Stéphane Champiat, Horst-Dieter Hummel, Kelly G. Paulson, Hossein Borghaei, Jean Bustamante Alvarez, David P. Carbone, Jennifer W. Carlisle, Noura J. Choudhury, Jeffrey M. Clarke, Shirish M. Gadgeel, Hiroki Izumi, Alejandro Navarro, Sally C. M. Lau, Philip E. Lammers, Shuang Huang, Ali Hamidi, Sujoy Mukherjee, Taofeek K. Owonikoko
medRxiv 2024.10.11.24315056; doi: https://doi.org/10.1101/2024.10.11.24315056
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area